Michael Gibson, PhD
Medical Oncology · Nashville, TNNPI 1649217969
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 29.2% of the total.
Across 150 payments — averaging $943.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$41K
- Daiichi Sankyo Inc.$32K
- Astellas Pharma Europe Ltd$13K
- Beone Medicines USA, Inc.$10K
- Regeneron$8K
- Merck$7K
- plus $30K from 15 others
Across 403 payments — averaging $3161.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$905K
- Incyte Corporation$163K
- Taiho Oncology, Inc.$70K
- Takeda Pharmaceuticals U.S.A., Inc.$42K
- Verastem, Inc.$41K
- Amgen$20K
- plus $33K from 4 others
What the payments were for
- Consulting fees$77,96255%
- Speaking & faculty fees$23,34917%
- Travel & lodging$35,24325%
- Food & beverage$4,9153%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 55 | $41,262 |
| Daiichi Sankyo Inc. | 11 | $32,446 |
| Astellas Pharma Europe Ltd | 5 | $12,838 |
| Beone Medicines USA, Inc. | 10 | $9,885 |
| Regeneron | 16 | $7,535 |
| Merck | 17 | $7,224 |
| Novartis | 3 | $7,075 |
| Jazz Pharmaceuticals Inc. | 3 | $6,450 |
| Coherus Oncology, Inc. | 5 | $4,063 |
| Beigene USA, Inc. | 2 | $3,490 |
| Regeneron Healthcare Solutions, Inc. | 2 | $2,874 |
| Fosun Pharma USA Inc. | 2 | $2,587 |
| Gilead | 2 | $2,298 |
| Bayer | 5 | $495 |
| AstraZeneca | 2 | $280 |
| Astellas Pharma US Inc | 5 | $223 |
| Celularity Inc. | 1 | $176 |
| Ipsen Biopharmaceuticals, Inc | 1 | $134 |
| Pfizer | 1 | $86 |
| Taiho Oncology, Inc. | 1 | $34 |
| Myovant Sciences Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$141,469 in reported general payments places this provider in the 85th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $11,348 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $2,366 |
| Gabapentin | 42 | $1,714 |
| Oxycodone Hcl | 54 | $595 |
| Esomeprazole Magnesium | 18 | $506 |
| Olanzapine | 15 | $337 |
| Dexamethasone | 37 | $272 |
| Ondansetron Hcl | 18 | $212 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 17 | $190 |
| Levothyroxine Sodium | 21 | $186 |
| Ondansetron OdtOndansetron | 12 | $184 |
| Duloxetine Hcl | 21 | $173 |
| Prochlorperazine Maleate | 11 | $171 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $169 |
| Potassium Chloride | 13 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $86 | $11,34814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 101 medical oncology providers in Tennessee.
Other medical oncology in Nashville
- William PaoNashville$838K
- Dana ThompsonNashville$339K
- Robert RamirezNashville$321K
- Mace RothenbergNashville$318K
- Melissa JohnsonNashville$290K
- Cathy EngNashville$231K
- David SpigelNashville$167K
- Jordan BerlinNashville$120K
- Vandana AbramsonNashville$98K
- Leora HornNashville$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.